18th July 2016
Roche Diagnostics puts technology into the hands of Point-of-Care Coordinators
Roche Diagnostics is today launching the first mobile and tablet application specifically designed to help point-of-care coordinators (POCCs) manage their workload remotely.
As the interface between pathology services and the ward, the demands on POCCs require them to complete much of their work away from a desk. This can be challenging, as managing many important tasks have traditionally required access to a PC. The cobas® infinity POC app from Roche Diagnostics changes this, by allowing POCCs to monitor the status of Roche and non-Roche devices from their mobile device and carry out most essential routine tasks with ease.
Following the successful pilots at five sites, this disruptive technology is now being rolled out across the UK and Ireland and is set to innovate the way POCCs work in the future, boosting productivity and placing the heart of the hospital into the hands of coordinators.
Adam Millard, Market Manager for Hospital Point of Care at Roche Diagnostics, said of the announcement: “We designed this app to empower POCCs. It has been developed by POCCs for POCCs, so we took everything we understood about the day-to-day pressures on their time and worked it into the app.
“Going mobile isn’t simply about transferring current processes to a phone or tablet. Its core value is about enabling operators to perform those essential tasks in the most efficient way based upon human interaction design principles. This gives our app a unique usability that will enable POCCs to carry out their essential routine tasks with ease.”
POCCs will be able to save time managing devices, automate operator management, train and certify device operators in real time without delay and act upon the most important priorities.
cobas® infinity POC app is compatible with both iOS and Android devices, works in real-time and in conjunction with the cobas® IT 1000 application.
For more details please contact roche@weare.ICG.com
About cobas® IT 1000
The cobas IT 1000 solution allows for management of system configurations, test and material management, operator and Point of Care instrument management, as well as quality control and extensive reporting functions. It connects the full Roche POC portfolio including Accu-Chek Inform II, CoaguChek XS Plus and Pro, cobas h 232, cobas b 101, Urisys 1100, cobas b 123, cobas b 221, as well as an evolving list of non-Roche devices. Find out more at www.cobas.com.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group
Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry seven years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.